Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Ranbaxy Laboratories Ltd, was a listed public company incorporated on 16 June, 1961. It is classified as a public limited company and is located in , Punjab. It's authorized share capital was INR 300.00 cr and the total paid-up capital was INR 212.83 cr.
The current status of Ranbaxy Laboratories Ltd is - Amalgamated.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
9.29%
7.69%
-68.97%
2.15%
6.23%
5.07%
5.57
-0.31
-8.37
-8.01
-0.76
0.01
No Reports Available
Tofler currently has no financial reports
for this company due to a lack of available
information. This may be because the company
is dormant or closed (see company status)
or because it was formed only recently
(check the incorporation date) and financial data
is not yet available.
You can view basic information by scrolling through the page.
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(1)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Rajesh Viren Shah | 00021752 | 16 years |
| Kmp | Sushil Kumar Patawari | <HIDDEN> | 29 years |
| Director | Arun Sawhney | 01929668 | 14 years |
| Director | Percy Keku Shroff | 02143003 | 16 years |
| Director | Takashi Shoda | 02436813 | 16 years |
| Director | Akihiro Watanabe | 02439360 | 16 years |
| Director | Tsutomu Une | 02439401 | 16 years |
| Director | Anthony Hugh Wild | 02454431 | 16 years |
| Director | Kazunori Hirokawa | 03562763 | 13 years |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Ranbaxy Pharmaceuticals Ukraine LLC | Ukraine | - | - |
| Ranbaxy Australia Pty. Ltd. | Australia | - | - |
| Ranbaxy-PRP (Peru) S.A.C. | Peru | - | - |
| Office Pharmaceutique Industrial Et | France | - | - |
| Be-Tabs Pharmaceuticals (Proprietary) Ltd. | South Africa | - | - |
| Ranbaxy Italia S.p.A Italy | Italy | - | - |
| Ranbaxy Pharma AB Sweden | Sweden | - | - |
| Ranbaxy Unichem Company Ltd. Thailand | Thailand | - | - |
| Ranbaxy GmbH | Germany | - | - |
| Ranbaxy Nigeria Ltd | Nigeria | - | - |
| Ranbaxy USA, Inc. | United States | - | - |
| Basics GmbH Germany | Germany | - | - |
| Ranbaxy, Inc, | United States | - | - |
| GUFIC PHARMA LIMITED | Gujarat | 1983 | ₹ 5.0 L |
| Ranbaxy Belgium N.V. Belgium | Belgium | - | - |
| REXCEL PHARMACEUTICALS LIMITED | Delhi | 1997 | ₹ 12.5 Cr |
| VIDYUT INVESTMENTS LIMITED | Punjab | 1988 | ₹ 25.0 Cr |
| Ranbaxy (S.A.) (Proprietory) | South Africa | - | - |
| Terapia Distributie SRL @ Romania | Romania | - | - |
| Rexcel Egypt (L.L.C.) | Egypt | - | - |
| SOLUS PHARMACEUTICALS LIMITED | Delhi | 1995 | ₹ 14.9 Cr |
| Terapia S.A. Romania | Romania | - | - |
| Ranbaxy (U.K.) Ltd. | United Kingdom | - | - |
| Ranbaxy Holdings (U.K.) Ltd | United Kingdom | - | - |
| Ranbaxy Malaysia Sdn. Bhd. | Malaysia | - | - |
| Laboratorios Ranbaxy, S.L. Spain | Spain | - | - |
| RANBAXY SEZ LIMITED | Punjab | 2008 | ₹ 5.0 L |
| Ranbaxy (Hong Kong) Limited | Hong Kong | - | - |
| Ranbaxy Ireland Ltd | Ireland | - | - |
| RANBAXY LIFE SCIENCES RESEARCH LIMITED | Punjab | 2006 | ₹ 5.1 Cr |
| Ranbaxy Poland S.P. Z.o.o. | Poland | - | - |
| Sonke Pharmaceuticals (Pty) Ltd | South Africa | - | - |
| Ranbaxy Pharmaceuticals Canada Inc. | Canada | - | - |
| RANBAXY DRUGS AND CHEMICALS COMPANY | Delhi | 1995 | ₹ 6.2 Cr |
| Ranbaxy Egypt (L.L.C.) | Egypt | - | - |
| Ranbaxy (S.A | Russian Federation | - | - |
| Ranbaxy Farmaceutica Ltda. Brazil | Brazil | - | - |
| Be-Tabs Investments (Proprietary)Ltd. | South Africa | - | - |
| Ranbaxy Pharmacie Generiques SAS | France | - | - |
| Ranbaxy Signature LLC | United States | - | - |
| RANBAXY DRUGS LIMITED | India | - | - |
| Ranbaxy Do Brazil Ltd | Brazil | - | - |
| Ranbaxy Portugal - Com E Desenvolv De Prod Farmaceuticos Unipessoal Lda Portugal | Portugal | - | - |
| Ranbaxy Pharmaceutical, Inc. | United States | - | - |
| Ranbaxy (Netherlands) B.V.(“RNBV”) | Netherlands | - | - |
| Ranbaxy Europe Ltd. | United Kingdom | - | - |
| Ohm Laboratories Inc. | United States | - | - |
| Ranbaxy Morocco LLC | Morocco | - | - |
| Ranbaxy Laboratories Inc. | United States | - | - |
The incorporation date of RANBAXY LABORATORIES LTD is 16 June, 1961
The authorized share capital of RANBAXY LABORATORIES LTD is INR ₹ 300.0 Cr.
The paid-up capital of RANBAXY LABORATORIES LTD is INR ₹ 212.8 Cr.
The registered address of RANBAXY LABORATORIES LTD is A-41 Industrial Area Phase VIII-A SAS Nagar Punjab - 160071
The CIN number of RANBAXY LABORATORIES LTD is L24231PB1961PLC003747.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
